PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3029% below fair value
$16.24+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $2.25BP/E –Yield 7.14%
Perrigo EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Perrigo's EPS for the twelve months ending Sep 26, 2026 was -$12.85. For fiscal 2025 it was -$10.29. The highest annual figure on record is $4.68 in fiscal 2013.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.29 | – |
| FY2024 | Dec 31, 2024 | -$1.25 | – |
| FY2023 | Dec 31, 2023 | -$0.09 | – |
| FY2022 | Dec 31, 2022 | -$1.04 | – |
| FY2021 | Dec 31, 2021 | -$0.52 | – |
| FY2020 | Dec 31, 2020 | -$1.19 | -211.2% |
| FY2019 | Dec 31, 2019 | $1.07 | +12.6% |
| FY2018 | Dec 31, 2018 | $0.95 | +13.1% |
| FY2017 | Dec 31, 2017 | $0.84 | -13.4% |
| FY2015 | Jun 27, 2015 | $0.97 | -51.7% |
| FY2014 | Jun 28, 2014 | $2.01 | -57.1% |
| FY2013 | Jun 29, 2013 | $4.68 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 26, 2026 | -$0.20 | -500.0% |
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $0.53 | – |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | -$2.87 | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$10.31 | – |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $0.05 | – |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | -$0.06 | – |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | -$0.05 | -600.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$0.32 | – |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | -$0.15 | -250.0% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | -$0.79 | -1416.7% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | $0.01 | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$0.25 | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $0.10 | – |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $0.06 | – |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | -$0.02 | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$0.18 | -357.1% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | -$0.37 | – |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | -$0.48 | – |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | -$0.02 | -107.1% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $0.07 | – |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | -$0.44 | – |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | -$0.43 | -197.7% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $0.28 | -63.6% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$1.29 | – |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | -$1.12 | -267.2% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $0.44 | +528.6% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $0.77 | +63.8% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$0.14 | -123.3% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $0.67 | – |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $0.07 | -73.1% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $0.47 | -17.5% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $0.60 | +15.4% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | -$0.49 | -258.1% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $0.26 | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $0.57 | +14.0% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $0.52 | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $0.31 | – |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | -$0.49 | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $0.50 | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | -$0.15 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?